Changes in quality of life (QOL) for patients (pts) enrolled in a phase III trial of treatment with a diphtheria toxin fusion protein (DAB(389)IL-2) for mycosis fungoides (MF). Liepa, A., Bennett, C. L., Yarnold, P. R., Enas, N., Lozano, J., Kuzel, T., Olson, E., Martin, A., Kim, Y., Duvic, M., Frankel, A., Vonderheid, E., Bowen, G., Jegasothy, B., Wood, G., Gordon, M., PINTERBROWN, L., Fivenson, D., Heald, P., Oscroff, A., Foss, F., Glode, M., Stewart, S., Molina, A., Knobler, E., Nichols, J. AMER SOC HEMATOLOGY. 1997: 3924–24

View details for Web of Science ID A1997YG42501234